Ming Xian

CIK 1743879 · last filed 2026-05-28

Ming Xian is a corporate insider who has filed 13 SEC Form 4 insider transactions across 1 company since 2019. The most recent filing, for MED, was dated May 28, 2026.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

Companies

Total Filings

Lifetime Open-Market Net

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

MED price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address

MEDIFAST, INC.
100 INTERNATIONAL DRIVE, 18TH FLOOR
BALTIMORE, MD 21202

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
MED	Director	—	$12.97	—	$0	13	2026-05-28

Recent Filings

13 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).

Filed	Symbol	Action	Net Shares	Net $	Link
2026-05-28	MED	Grant (A)	—	$0	EDGAR
2025-06-26	MED	Grant (A)	—	$0	EDGAR
2024-06-24	MED	Grant (A)	—	$0	EDGAR
2023-11-09	MED	Buy (P)	—	$0	EDGAR
2023-08-10	MED	Buy (P)	—	$0	EDGAR
2023-06-20	MED	Grant (A)	—	$0	EDGAR
2023-05-11	MED	Buy (P)	—	$0	EDGAR
2023-02-09	MED	Grant (A)	—	$0	EDGAR
2022-08-10	MED	Grant (A)	—	$0	EDGAR
2022-06-21	MED	Grant (A)	—	$0	EDGAR

Showing 1–10 of 13

Page 1 of 2 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).